drugset / Trial / NCT07847905
A Phase I/II Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors. For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.
Timeline
- Start
- 2026-10-19
- Primary completion
- 2030-10-19
- Completion
- 2031-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LM-364 | Unknown | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.